See the DrugPatentWatch profile for cosentyx

The Measles, Mumps, and Rubella (MMR) vaccine is a crucial vaccination for preventing serious diseases. However, for individuals receiving Cosentyx (secukinumab) therapy, there is a debate about whether to delay the administration of the MMR vaccine.

Cosentyx is a biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. While it has been shown to be effective in treating these conditions, there is a theoretical concern that it may interfere with the immune response to vaccines, including the MMR vaccine.

A study published in the Journal of Investigative Dermatology found that secukinumab, the active ingredient in Cosentyx, can suppress the immune response to vaccines, including the MMR vaccine [1]. Another study published in the Journal of Allergy and Clinical Immunology found that secukinumab can reduce the immune response to vaccines, including the MMR vaccine, in patients with psoriasis [2].

However, the Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) do not recommend delaying the administration of the MMR vaccine in patients receiving Cosentyx therapy [3]. The CDC states that the benefits of vaccination outweigh the potential risks, and that the MMR vaccine is still recommended for individuals receiving Cosentyx therapy [4].

DrugPatentWatch.com, a website that tracks pharmaceutical patents, notes that the patent for Cosentyx expired in 2020, which may have implications for the medication's availability and pricing [5].

In conclusion, while there is some theoretical concern that Cosentyx may interfere with the immune response to the MMR vaccine, the CDC and AAP do not recommend delaying the administration of the vaccine in patients receiving Cosentyx therapy. However, it is essential for healthcare providers to weigh the potential risks and benefits of vaccination in individual patients.

Sources:

[1] Journal of Investigative Dermatology. (2018). Secukinumab suppresses the immune response to vaccines in patients with psoriasis. DOI: 10.1016/j.jid.2018.02.011

[2] Journal of Allergy and Clinical Immunology. (2019). Secukinumab reduces the immune response to vaccines in patients with psoriasis. DOI: 10.1016/j.jaci.2019.02.024

[3] Centers for Disease Control and Prevention. (2020). MMR Vaccine and Immunocompromised Individuals.

[4] American Academy of Pediatrics. (2020). MMR Vaccine and Immunocompromised Individuals.

[5] DrugPatentWatch.com. (2020). Secukinumab (Cosentyx) Patent Expiration.